<p><h1>Inhaled Nitric Oxide Market Size Growing and Forecasted for period from 2024 - 2031 and provides complete market analysis of this market</h1></p><p><strong>Inhaled Nitric Oxide Market Analysis and Latest Trends</strong></p>
<p><p>Inhaled Nitric Oxide (iNO) is a colorless gas that is administered through inhalation to provide selective pulmonary vasodilation. It is primarily used in the treatment of pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. By relaxing and dilating the smooth muscle cells in these arteries, inhaled nitric oxide helps improve blood flow and oxygenation to the lungs.</p><p>The global market for inhaled nitric oxide has witnessed significant growth in recent years. The growing prevalence of pulmonary hypertension, along with advancements in healthcare infrastructure and increasing awareness about respiratory diseases, has fueled the demand for inhaled nitric oxide. Additionally, the rising geriatric population, who are more susceptible to respiratory ailments, has further contributed to the market growth.</p><p>Moreover, the COVID-19 pandemic has also boosted the adoption of inhaled nitric oxide, as it has shown potential in treating acute respiratory distress syndrome (ARDS) associated with the virus. Furthermore, ongoing research and development activities to expand the application of iNO in other respiratory diseases are expected to drive market growth.</p><p>Some of the latest trends in the inhaled nitric oxide market include the development of portable and user-friendly iNO delivery devices, increasing collaborations and partnerships among key players in the market, and growing investment in research and development.</p><p>According to the forecast, the inhaled nitric oxide market is projected to grow at a compound annual growth rate (CAGR) of 7.50% during the forecast period. This growth can be attributed to the factors mentioned above, in addition to the increasing demand for personalized medicine and the development of innovative iNO delivery systems. Furthermore, the market is expected to witness significant expansion in emerging economies due to improving healthcare infrastructure and increasing disposable income.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1016033">https://www.reliableresearchreports.com/enquiry/request-sample/1016033</a></p>
<p>&nbsp;</p>
<p><strong>Inhaled Nitric Oxide Major Market Players</strong></p>
<p><p>The inhaled nitric oxide market is highly competitive with several key players dominating the industry. Some of the major players in the market include Mallinckrodt, Praxair (Linde plc), Air Liquide, and BOC Healthcare (Linde Group).</p><p>Mallinckrodt is a leading global specialty pharmaceutical company that focuses on respiratory therapies and critical care products. The company offers inhaled nitric oxide under the brand name INOmax. Mallinckrodt's INOmax is the only FDA-approved inhaled nitric oxide therapy for the treatment of neonates with hypoxic respiratory failure. The company has been experiencing steady market growth due to the rising incidence of respiratory diseases. Mallinckrodt's strong product portfolio and focus on research and development have positioned the company as a key player in the inhaled nitric oxide market.</p><p>Praxair, now part of Linde plc, is a leading industrial gas company that also offers inhaled nitric oxide as a therapeutic gas. The company's inhaled nitric oxide therapy is primarily used for the treatment of neonatal hypoxemic respiratory failure. Praxair's strong distribution network and established presence in the healthcare industry have contributed to its market growth. With the recent merger with Linde, the company is expected to further expand its market reach and product offerings.</p><p>Air Liquide is another prominent player in the inhaled nitric oxide market. The company has a wide range of healthcare solutions and offers inhaled nitric oxide therapy under the brand name iNOvent. Air Liquide's iNOvent is used for the treatment of persistent pulmonary hypertension in newborns. The company has a strong global presence and focuses on continuous innovation to cater to the changing healthcare needs. Air Liquide's commitment to sustainable development and investment in R&D are important factors driving its market growth.</p><p>BOC Healthcare, a subsidiary of the Linde Group, is a leading provider of medical gases, including inhaled nitric oxide. The company's inhaled nitric oxide therapy is primarily used for the treatment of newborns with severe hypoxemic respiratory failure. BOC Healthcare has a strong reputation for delivering high-quality medical gases and has a widespread presence in several regions. The company's ability to provide customized solutions and value-added services has contributed to its market growth.</p><p>As for market size and sales revenue, specific figures may not be available for these companies. However, the global inhaled nitric oxide market was valued at approximately USD 750 million in 2020, and it is expected to witness significant growth in the coming years. Factors such as increased prevalence of respiratory diseases, growing neonatal population, and advancements in healthcare infrastructure are driving the market growth. Additionally, the introduction of new products and therapies by key players is expected to further fuel market expansion.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Inhaled Nitric Oxide Manufacturers?</strong></p>
<p><p>The inhaled nitric oxide market is experiencing significant growth trends due to its increasing applications in the treatment of various respiratory diseases. The market is expected to witness a substantial CAGR in the coming years, driven by the rising prevalence of chronic obstructive pulmonary disease (COPD) and the growing geriatric population. Additionally, advancements in healthcare infrastructure and an increase in research and development activities are fueling market growth. Furthermore, the future outlook of the inhaled nitric oxide market looks promising, with potential opportunities in emerging economies and the development of innovative treatment modalities.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1016033">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1016033</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Inhaled Nitric Oxide Market Analysis by types is segmented into:</strong></p>
<p><ul><li>800 ppm</li><li>100 ppm</li><li>Others</li></ul></p>
<p><p>The inhaled nitric oxide market is classified into various types based on the concentration of nitric oxide in parts per million (ppm). The 800 ppm market represents the segment where nitric oxide is administered at a concentration of 800 parts per million. Similarly, the 100 ppm market refers to the administration of nitric oxide at a concentration of 100 parts per million. Apart from these, there are also other concentrations available in the market, which do not fall into the specifically mentioned categories. These different concentrations cater to varying medical requirements and treatment protocols.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1016033">https://www.reliableresearchreports.com/purchase/1016033</a></p>
<p>&nbsp;</p>
<p><strong>The Inhaled Nitric Oxide Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Near-term and Pre-term Infants PPHN</li><li>Children and Adult ARDS</li><li>Other Diseases</li></ul></p>
<p><p>The application of inhaled nitric oxide in the market caters to various medical conditions. It is used in near-term and pre-term infants with a condition called persistent pulmonary hypertension (PPHN), which affects their ability to breathe properly. Additionally, it is also utilized in treating acute respiratory distress syndrome (ARDS) in children and adults. Furthermore, inhaled nitric oxide finds application in treating other diseases, although specific details about these conditions are not provided.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Inhaled Nitric Oxide Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The inhaled nitric oxide market is anticipated to witness significant growth across various regions, including North America (NA), Asia-Pacific (APAC), Europe, the United States of America (USA), and China. North America is expected to dominate the market, accounting for a notable market share percentage, primarily attributed to the presence of well-established healthcare infrastructure and increasing prevalence of respiratory disorders. Europe and the USA are also projected to hold substantial market shares, owing to rising advancements in medical technology and growing investments in research and development. Meanwhile, China and the APAC region are expected to exhibit significant market growth due to increasing healthcare expenditure and a high patient population.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1016033">https://www.reliableresearchreports.com/purchase/1016033</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1016033">https://www.reliableresearchreports.com/enquiry/request-sample/1016033</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>